Treatment-emergent adverse events and compliance
TEAEs, Treatment-emergent adverse
TEAEs occurred in 16 patients in the L-VA dual therapy group and in 11 patients in the H-VA dual therapy group. One patient in the L-VA group presented moderate TEAEs. No patients discontinued the administration of study drugs because of TEAEs. The incidence of TEAEs between the two groups was not statistically different (29.1% vs. 20.0%, P=0.268) (Treatment-emergent adverse events and patient compliance of each treatment group (n, %).L-VA, dual therapy consisting of low-dose amoxicillin (1000 mg b.i.d.) and vonoprazan (20 mg b.i.d.); H-VA, dual therapy consisting of high-dose amoxicillin (1000 mg t.i.d.) and vonoprazan (20 mg b.i.d.).Factors influencing cure rates in the per-protocol population.BMI, body mass index; L-VA, dual therapy consisting of low-dose amoxicillin (1000 mg b.i.d.) and vonoprazan (20 mg b.i.d.); H-VA, dual therapy consisting of high-dose amoxicillin (1000 mg t.i.d.) and vonoprazan (20 mg b.i.d.).